Biomm S.A. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was BRL 104.95 million compared to BRL 107.09 million a year ago. Net loss was BRL 92.56 million compared to BRL 80.26 million a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
15.97 BRL | -2.38% | -11.28% | +176.30% |
Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
Apr. 17 | Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A | CI |
1st Jan change | Capi. | |
---|---|---|
+176.30% | 277M | |
+8.71% | 114B | |
+11.13% | 104B | |
-12.73% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.08% | 17.89B | |
+7.73% | 14.28B | |
+35.20% | 12.55B |
- Stock Market
- Equities
- BIOM3 Stock
- News Biomm S.A.
- Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022